Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
Status:
Completed
Trial end date:
2020-11-30
Target enrollment:
Participant gender:
Summary
Phase II study to investigate the antitumor activity in terms of objective response rate
(ORR) of tipifarnib in subjects with advanced tumors that carry HRAS mutations and for whom
there is no standard curative therapy available. Note; Only cohort 2 (Head & Neck SCC) and
cohort 3 (Other SCC) are currently open